RELIEF THERAPEUTICS Holding SA announced the appointment, effective December 1, 2021, of Anthony M. Kim as Senior Vice President and Head of U.S. Commercial Operations. The company also reported that Chris Stijnen, Chief Commercial Officer since 2020, will be leaving to pursue other opportunities effective November 30, 2021. His duties regarding EU and UK commercial operations will be assumed by Paolo Galfetti, President of Relief Europe, and the commercial team at Relief's subsidiary, APR Applied Pharma Research SA ("APR"). Prior to joining Relief, for the past three years, Mr. Kim was Vice President, Global Commercial Development at Novocure, where he led a 21-person team in the planning and U.S. marketing execution for that company's Optune(R) and Optune Lua(TM), FDA-approved, therapeutic devices that deliver alternating electrical fields to treat patients with Glioblastoma Multiforme and Mesothelioma. From 2017 to 2018, he was Executive Director of Marketing at Ignyta (subsequently acquired by Roche), during which time he led the development of the commercial launch plan for entrectinib, an oral, oncologic agent in pan-tumor clinical trials for patients with neurotrophic tyrosine receptor kinase (NTRK) and ROS1 fusion-positive disease.